

```
=> fil hcaplus
FILE 'HCAPLUS' ENTERED AT 08:15:24 ON 22 OCT 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)
```

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.



FILE COVERS 1907 - 22 Oct 2002 VOL 137 ISS 17
FILE LAST UPDATED: 21 Oct 2002 (20021021/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

CAS roles have been modified effective December 16, 2001. Please check your SDI profiles to see if they need to be revised. For information on CAS roles, enter HELP ROLES at an arrow prompt or use the CAS Roles thesaurus (/RL field) in this file.

$$\Rightarrow$$

=> d stat que
L1 STR




```
REP G1=(0-1) N
VAR G2=16/18/21/24/25/27/29/31/32
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED
```

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 36

STEREO ATTRIBUTES: NONE

L2 241 SEA FILE=REGISTRY SSS FUL L1
L3 STR




REP G1=(0-1) N
VAR G2=16/18/21/24/25/27/29/31/32
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 36

STEREO ATTRIBUTES: NONE

L4 (241)SEA FILE=REGISTRY SSS FUL L3
L5 STR



REP G1=(0-1) N
 VAR G2=16/18/21/24/25/27/29/31/32
 VAR G3=39/46/47/48
 NODE ATTRIBUTES:
 DEFAULT MLEVEL IS ATOM
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
 RING(S) ARE ISOLATED OR EMBEDDED
 NUMBER OF NODES IS 52


STEREO ATTRIBUTES: NONE
 L6 100 SEA FILE=REGISTRY SUB=L4 SSS FUL L5
 L10 12 SEA FILE=HCAPLUS ABB=ON PLU=ON L2
 L11 3 SEA FILE=HCAPLUS ABB=ON PLU=ON L6
 L12 9 SEA FILE=HCAPLUS ABB=ON PLU=ON L10 NOT L11

=>
 =>

=> d ibib abs hitstr l12 1-9

L12 ANSWER 1 OF 9 HCAPLUS COPYRIGHT 2002 ACS
 ACCESSION NUMBER: 2002:72030 HCAPLUS
 DOCUMENT NUMBER: 136:134761
 TITLE: Preparation of 3-arylsulfonyl-2-hydroxy-2-methylpropanoic acids as inhibitors of matrix metallo-proteinases (MMPs)
 INVENTOR(S): Mantegani, Sergio; Bissolino, Pierluigi; Abrate, Francesca; Cremonesi, Paolo; Perrone, Ettore
 PATENT ASSIGNEE(S): Pharmacia & Upjohn S.p.A., Italy
 SOURCE: PCT Int. Appl., 50 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002006215	A1	20020124	WO 2001-EP7736	20010705
<p>W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM</p> <p>RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG</p>				
PRIORITY APPLN. INFO.:			GB 2000-17435 A 20000714	
OTHER SOURCE(S):			MARPAT 136:134761	
GI				



I

AB The title compds. [I; X = NHOH, OH; R1 = OPh, SPh, SHet, Hyd, CH2Hyd; Het = heterocyclic ring; Hyd = substituted hydantoin-3-yl ring; A = Ph, Het, condensed Ph ring; R2 = H, Me; or R2 represents a methylene bridge connecting the N atom to the ortho position of said A to form a 5-membered lactam] or their salts which are inhibitors of matrix metallo-proteinases (MMPs) and are therefore useful in the prevention, control and treatment of diseases in which MMPs are involved, were prepd. E.g., a multi-step synthesis of I [A = 4-ClC6H4; X = OH; R1 = (3,4,4-trimethylhydantoin-1-yl)CH2; R2 = H] which showed Ki of 14.7 nM against MMP-2, was given.


IT 391903-55-2P 391903-56-3P 391903-57-4P
 391903-58-5P 391903-59-6P 391903-60-9P
 391903-61-0P 391903-62-1P 391903-63-2P
 391903-64-3P 391903-65-4P 391903-66-5P
 391903-67-6P 391903-68-7P 391903-69-8P
 391903-70-1P 391903-71-2P 391903-72-3P
 391903-73-4P 391903-74-5P 391903-75-6P
 391903-76-7P 391903-77-8P 391903-78-9P
 391903-79-0P 391904-13-5P 391904-15-7P
 391904-16-8P 391904-18-0P 391904-19-1P
 391904-22-6P 391904-23-7P 391904-24-8P
 391904-25-9P 391904-26-0P 391904-27-1P
 391904-28-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of 3-arylsulfonyl-2-hydroxy-2-methylpropanoic acids as inhibitors of matrix metallo-proteinases (MMPs))


RN 391903-55-2 HCAPLUS

CN Propanoic acid, 3-[[4-[(4-chlorobenzoyl)amino]phenyl]sulfonyl]-2-hydroxy-2-[(phenylthio)methyl]- (9CI) (CA INDEX NAME)




RN 391903-56-3 HCAPLUS

CN Propanoic acid, 2-hydroxy-2-[[[4-[(4-methoxybenzoyl)amino]phenyl]sulfonyl]methyl]-3-(phenylthio)- (9CI) (CA INDEX NAME)




RN 391903-57-4 HCAPLUS

CN Propanoic acid, 2-hydroxy-2-[(phenylthio)methyl]-3-[[4-[(4-pyridinylcarbonyl)amino]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 391903-58-5 HCAPLUS

CN Propanoic acid, 3-[[4-[(1,3-benzodioxol-5-ylcarbonyl)amino]phenyl]sulfonyl]-2-hydroxy-2-[(phenylthio)methyl]- (9CI) (CA INDEX NAME)



RN 391903-59-6 HCAPLUS


CN Propanoic acid, 3-[[4-[[4-(dimethylamino)benzoyl]amino]phenyl]sulfonyl]-2-hydroxy-2-[(phenylthio)methyl]-, monosodium salt (9CI). (CA INDEX NAME)



● Na


RN 391903-60-9 HCAPLUS

CN Propanoic acid, 3-[[4-[(4-chlorobenzoyl)amino]phenyl]sulfonyl]-2-hydroxy-2-(phenoxy)methyl]- (9CI) (CA INDEX NAME)




RN 391903-61-0 HCAPLUS

CN Propanoic acid, 3-[[4-[(4-fluorobenzoyl)amino]phenyl]sulfonyl]-2-hydroxy-2-(phenoxy)methyl]- (9CI) (CA INDEX NAME)




RN 391903-62-1 HCAPLUS

CN Propanoic acid, 3-[[4-[(4-cyanobenzoyl)amino]phenyl]sulfonyl]-2-hydroxy-2-(phenoxy)methyl]- (9CI) (CA INDEX NAME)




RN 391903-63-2 HCAPLUS

CN Propanoic acid, 2-hydroxy-2-(phenoxy)methyl)-3-[[4-[(4-pyridinylcarbonyl)amino]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 391903-64-3 HCAPLUS

CN Propanoic acid, 3-[[4-[(4-bromobenzoyl)amino]phenyl]sulfonyl]-2-hydroxy-2-(phenoxy)methyl)- (9CI) (CA INDEX NAME)



RN 391903-65-4 HCAPLUS


CN Propanoic acid, 3-[[4-[[4-(dimethylamino)benzoyl]amino]phenyl]sulfonyl]-2-hydroxy-2-(phenoxy)methyl)-, monosodium salt (9CI) (CA INDEX NAME)



● Na

RN 391903-66-5 HCAPLUS


CN Propanoic acid, 2-hydroxy-2-[[[4-[(4-methoxybenzoyl)amino]phenyl]sulfonyl]methyl]-3-phenoxy- (9CI) (CA INDEX NAME)



RN 391903-67-6 HCAPLUS


CN Propanoic acid, 3-[[4-[(1,3-benzodioxol-5-ylcarbonyl)amino]phenyl]sulfonyl

] -2-hydroxy-2-(phenoxyethyl)- (9CI) (CA INDEX NAME)




RN 391903-68-7 HCAPLUS

CN Propanoic acid, 3-[[4-(benzoylamino)phenyl]sulfonyl]-2-hydroxy-2-(phenoxyethyl)- (9CI) (CA INDEX NAME)




RN 391903-69-8 HCAPLUS

CN Propanoic acid, 3-[[4-(1,3-dihydro-1-oxo-2H-isoindol-2-yl)phenyl]sulfonyl]-2-hydroxy-2-(phenoxyethyl)- (9CI) (CA INDEX NAME)




RN 391903-70-1 HCAPLUS

CN Propanoic acid, 3-[[4-[(4-chlorobenzoyl)methylamino]phenyl]sulfonyl]-2-hydroxy-2-(phenoxyethyl)- (9CI) (CA INDEX NAME)




RN 391903-71-2 HCAPLUS


CN Propanoic acid, 3-[[4-[(4-chlorobenzoyl)amino]phenyl]sulfonyl]-2-hydroxy-2-[(2-thiazolylthio)methyl]- (9CI) (CA INDEX NAME)




RN 391903-72-3 HCAPLUS
CN Propanoic acid, 3-[[4-[(4-chlorobenzoyl)amino]phenyl]sulfonyl]-2-hydroxy-2-[(2-pyridinylthio)methyl]- (9CI) (CA INDEX NAME)




RN 391903-73-4 HCAPLUS
CN Propanoic acid, 3-[[4-[(4-chlorobenzoyl)amino]phenyl]sulfonyl]-2-hydroxy-2-[[4-(hydroxyphenyl)thio]methyl]- (9CI) (CA INDEX NAME)



RN 391903-74-5 HCAPLUS
CN Propanoic acid, 3-[[4-[(4-chlorobenzoyl)amino]phenyl]sulfonyl]-2-[[4-(fluorophenyl)thio]methyl]-2-hydroxy- (9CI) (CA INDEX NAME)




RN 391903-75-6 HCAPLUS
CN Benzamide, 4-chloro-N-[4-[[2-hydroxy-3-(hydroxyamino)-3-oxo-2-(phenoxy)methyl]propyl]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)




RN 391903-76-7 HCAPLUS
 CN 1-Imidazolidinepropanoic acid, .alpha.-[[[4-[(4-chlorobenzoyl)amino]phenyl]sulfonyl]methyl]-.alpha.-hydroxy-3,4,4-trimethyl-2,5-dioxo- (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 391903-77-8 HCAPLUS
 CN Propanoic acid, 2-hydroxy-2-(phenoxyethyl)-3-[[[4-[(4-(trifluoromethoxy)benzoyl)amino]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 391903-78-9 HCAPLUS

CN Propanoic acid, 2-hydroxy-2-(phenoxyethyl)-3-[[4-[[4-(trifluoromethyl)benzoyl]amino]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 391903-79-0 HCAPLUS

CN Propanoic acid, 3-[[4-[(4-fluorobenzoyl)amino]phenyl]sulfonyl]-2-hydroxy-2-[[4-(4-hydroxyphenyl)thio]methyl]- (9CI) (CA INDEX NAME)



RN 391904-13-5 HCAPLUS


CN Propanoic acid, 3-[[4-[(1H-benzotriazol-5-ylcarbonyl)amino]phenyl]sulfonyl]-2-hydroxy-2-(phenoxyethyl)- (9CI) (CA INDEX NAME)




RN 391904-15-7 HCAPLUS

CN Propanoic acid, 3-[[4-[(4-chlorobenzoyl)amino]phenyl]sulfonyl]-2-hydroxy-2-[(phenylthio)methyl]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 391904-16-8 HCAPLUS
 CN Propanoic acid, 3-[[4-[(4-chlorobenzoyl)amino]phenyl]sulfonyl]-2-hydroxy-2-
 [(2-thiazolylthio)methyl]-, monosodium salt (9CI) (CA INDEX NAME)




● Na

RN 391904-18-0 HCAPLUS
 CN Propanoic acid, 3-[[4-[(4-chlorobenzoyl)amino]phenyl]sulfonyl]-2-hydroxy-2-
 [(2-pyridinylthio)methyl]-, monosodium salt (9CI) (CA INDEX NAME)




● Na

RN 391904-19-1 HCAPLUS
 CN Propanoic acid, 3-[[4-[(4-fluorobenzoyl)amino]phenyl]sulfonyl]-2-hydroxy-2-
 [(phenylthio)methyl]- (9CI) (CA INDEX NAME)




RN 391904-22-6 HCAPLUS
 CN Propanoic acid, 2-hydroxy-2-(phenoxymethyl)-3-[[4-[[4-(1-pyrrolidinyl)benzoyl]amino]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 391904-23-7 HCAPLUS

CN Propanoic acid, 3-[[4-[[[(6-chloro-3-pyridinyl)carbonyl]amino]phenyl]sulfonyl]-2-hydroxy-2-(phenoxymethyl)- (9CI) (CA INDEX NAME)




RN 391904-24-8 HCAPLUS

CN Propanoic acid, 2-hydroxy-2-[(phenylthio)methyl]-3-[[4-[(4-propoxybenzoyl)amino]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 391904-25-9 HCAPLUS


CN Propanoic acid, 2-hydroxy-2-[(phenylthio)methyl]-3-[[4-[[4-(trifluoromethoxy)benzoyl]amino]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 391904-26-0 HCAPLUS
 CN Propanoic acid, 2-hydroxy-2-[(phenylthio)methyl]-3-[[4-[[4-(trifluoromethyl)benzoyl]amino]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 391904-27-1 HCAPLUS
 CN 1,3-Benzodioxole-5-carboxamide, N-[4-[[2-hydroxy-3-(hydroxyamino)-3-oxo-2-(phenoxy)methyl]propyl]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 391904-28-2 HCAPLUS
 CN Propanamide, 3-[[4-(1,3-dihydro-1-oxo-2H-isoindol-2-yl)phenyl]sulfonyl]-N,2-dihydroxy-2-(phenoxy)methyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L12 ANSWER 2 OF 9 HCAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1998:788776 HCAPLUS

DOCUMENT NUMBER: 130:52234


TITLE: Preparation of .beta.-benzenesulfonyl hydroxamic acids as inhibitors of matrix metalloproteinases involved in

CN Propanamide, 3-[(4-chlorophenyl)sulfonyl]-2-[[(4-chlorophenyl)sulfonyl]methyl]-N-hydroxy- (9CI) (CA INDEX NAME)




RN 205504-42-3 HCAPLUS

CN Propanamide, 3-[(4-bromophenyl)sulfonyl]-2-[[(4-bromophenyl)sulfonyl]methyl]-N-hydroxy- (9CI) (CA INDEX NAME)




RN 205504-45-6 HCAPLUS

CN Propanamide, N-hydroxy-3-[(4-methylphenyl)sulfonyl]-2-[[(4-methylphenyl)sulfonyl]methyl]- (9CI) (CA INDEX NAME)



RN 205504-46-7 HCAPLUS

CN Propanamide, N-hydroxy-3-(phenylsulfonyl)-2-[(phenylsulfonyl)methyl]- (9CI) (CA INDEX NAME)




RN 205504-49-0 HCAPLUS

CN 1-Imidazolidinepropanamide, N-hydroxy-.alpha.-[[(4-methoxyphenyl)sulfonyl]methyl]-3-methyl-2,5-dioxo- (9CI) (CA INDEX NAME)

INVENTOR(S): Warpehoski, Martha A.; Harper, Donald E.
 PATENT ASSIGNEE(S): Pharmacia & Upjohn Company, USA
 SOURCE: U.S., 19 pp.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5847153	A	19981208	US 1997-934408	19970919

OTHER SOURCE(S): MARPAT 130:52234
 GI




AB The title compds. [I; R1 = C4-12 alkyl, C4-12 alkenyl, C4-12 alkynyl, etc.; R2 = (un)substituted C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, etc.], inhibitors of matrix metalloproteinases involved in tissue degrdn. such as stromelysin, collagenase and gelatinase, and therefore useful in the treatment of osteoarthritis, rheumatoid arthritis, septic arthritis, osteopenia, osteoporosis, tumor metastasis, periodontitis, gingivitis, corneal epidermal ulceration or gastric ulceration, were prepd. Thus, 6-step synthesis of the title compd. II, starting with benzylmalonic acid di-Et ester, which showed Ki of 0.049 .mu.M and 0.0092 .mu.M against stromelysin and gelatinase, resp., was described.

IT 205504-40-1P 205504-41-2P 205504-42-3P
 205504-45-6P 205504-46-7P 205504-49-0P
 205504-50-3P 205504-51-4P 205504-52-5P
 205504-55-8P 205504-56-9P 205504-57-0P
 205504-58-1P 205504-59-2P 205504-60-5P
 205504-61-6P 205504-62-7P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of .beta.-benzenesulfonyl hydroxamic acids as inhibitors of matrix metalloproteinases involved in tissue degrdn.)

RN 205504-40-1 HCAPLUS

CN Propanamide, N-hydroxy-3-[(4-methoxyphenyl)sulfonyl]-2-[[4-methoxyphenyl)sulfonyl)methyl]- (9CI) (CA INDEX NAME)




RN 205504-41-2 HCAPLUS




RN 205504-50-3 HCAPLUS

CN 1-Imidazolidinepropanamide, .alpha.-[[(4-butoxyphenyl) sulfonyl]methyl]-3-butyl-N-hydroxy-2,5-dioxo- (9CI) (CA INDEX NAME)




RN 205504-51-4 HCAPLUS

CN 1-Imidazolidinepropanamide, 3-butyl-N-hydroxy-.alpha.-[[(4-methoxyphenyl) sulfonyl]methyl]-2,5-dioxo- (9CI) (CA INDEX NAME)




RN 205504-52-5 HCAPLUS
 CN 1-Imidazolidinepropanamide, N-hydroxy-.alpha.-[[(4-methoxyphenyl)sulfonyl]methyl]-4,4-dimethyl-2,5-dioxo- (9CI) (CA INDEX NAME)




RN 205504-55-8 HCAPLUS
 CN 1-Imidazolidinepropanamide, N-hydroxy-.alpha.-[[(4-methoxyphenyl)sulfonyl]methyl]-3-methyl-2,5-dioxo-, (+)- (9CI) (CA INDEX NAME)

Rotation (+).




RN 205504-56-9 HCAPLUS
 CN 1-Imidazolidinepropanamide, N-hydroxy-.alpha.-[[(4-methoxyphenyl)sulfonyl]methyl]-3-methyl-2,5-dioxo-, (-)- (9CI) (CA INDEX NAME)

Rotation (-).




RN 205504-57-0 HCAPLUS
 CN 1-Imidazolidinepropanamide, .alpha.-[[(4-butoxyphenyl)sulfonyl]methyl]-3-butyl-N-hydroxy-2,5-dioxo-, (+)- (9CI) (CA INDEX NAME)

Rotation (+).



RN 205504-58-1 HCAPLUS
 CN 1-Imidazolidinepropanamide, .alpha.-[[(4-butoxyphenyl)sulfonyl]methyl]-3-butyl-N-hydroxy-2,5-dioxo-, (-)- (9CI) (CA INDEX NAME)


Rotation (-).



RN 205504-59-2 HCAPLUS

CN 1-Imidazolidinepropanamide, 3-butyl-N-hydroxy-.alpha.-[[[4-methoxyphenyl)sulfonyl]methyl]-2,5-dioxo-, (+)-(9CI) (CA INDEX NAME)


Rotation (+).



RN 205504-60-5 HCAPLUS

CN 1-Imidazolidinepropanamide, 3-butyl-N-hydroxy-.alpha.-[[[4-methoxyphenyl)sulfonyl]methyl]-2,5-dioxo-, (-)-(9CI) (CA INDEX NAME)


Rotation (-).



RN 205504-61-6 HCAPLUS


CN 1-Imidazolidinepropanamide, N-hydroxy-.alpha.-[[[4-methoxyphenyl)sulfonyl]methyl]-4,4-dimethyl-2,5-dioxo-, (+)-(9CI) (CA INDEX NAME)

Rotation (+).



RN 205504-62-7 HCAPLUS
 CN 1-Imidazolidinepropanamide, N-hydroxy-.alpha.-[[[4-methoxyphenyl)sulfonyl)methyl]-4,4-dimethyl-2,5-dioxo-, (-)- (9CI) (CA INDEX NAME)


Rotation (-).




IT 205504-67-2P 205504-68-3P 205504-70-7P
 205504-74-1P 205504-87-6P 205504-88-7P
 205504-90-1P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. of .beta.-benzenesulfonyl hydroxamic acids as inhibitors of matrix metalloproteinases involved in tissue degrdn.)

RN 205504-67-2 HCAPLUS
 CN Propanoic acid, 3-[[[4-methoxyphenyl)thio]-2-[[[4-methoxyphenyl)thio]methyl]- (9CI) (CA INDEX NAME)




RN 205504-68-3 HCAPLUS
 CN Propanoic acid, 3-[[[4-methoxyphenyl)sulfonyl]-2-[[[4-methoxyphenyl)sulfonyl)methyl]- (9CI) (CA INDEX NAME)




RN 205504-70-7 HCAPLUS

CN Propanoic acid, 3-[(4-chlorophenyl)sulfonyl]-2-[[4-chlorophenyl)sulfonyl)methyl]- (9CI) (CA INDEX NAME)




RN 205504-74-1 HCAPLUS

CN Propanoic acid, 3-[(4-methylphenyl)sulfonyl]-2-[[4-methylphenyl)sulfonyl)methyl]- (9CI) (CA INDEX NAME)




RN 205504-87-6 HCAPLUS

CN 1-Imidazolidinepropanoic acid, .alpha.-[[4-methoxyphenyl)thio]methyl]-3-methyl-2,5-dioxo- (9CI) (CA INDEX NAME)




RN 205504-88-7 HCAPLUS

CN 1-Imidazolidinepropanoic acid, .alpha.-[[4-methoxyphenyl)sulfonyl)methyl]-3-methyl-2,5-dioxo- (9CI) (CA INDEX NAME)




RN 205504-90-1 HCAPLUS
 CN 1-Imidazolidinepropanoic acid, .alpha.-[[[4-butoxyphenyl)sulfonyl]methyl]-
 3-butyl-2,5-dioxo- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L12 ANSWER 3 OF 9 HCAPLUS COPYRIGHT 2002 ACS
 ACCESSION NUMBER: 1998:414737 HCAPLUS
 DOCUMENT NUMBER: 129:67777
 TITLE: Preparation of antiviral 5,5-disubstituted hydantoins
 INVENTOR(S): Comber, Robert N.; Reynolds, Robert C.; Buckheit,
 Robert W., Jr.
 PATENT ASSIGNEE(S): Southern Research Institute, USA
 SOURCE: U.S., 9 pp., Cont.-in-part of U.S. Ser. No. 945,208,



abandoned.
CODEN: USXXAM
Patent
English

DOCUMENT TYPE:
LANGUAGE:
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5767140	A	19980616	US 1995-403339	19950314
PRIORITY APPLN. INFO.:			US 1992-945208	19920915
OTHER SOURCE(S):	MARPAT 129:67777			
GI				




AB A series of 5,5-disubstituted hydantoin derivs. I (R, R1 = thiomethyl cyclic, thioaliph., thioalkyl cyclic) were synthesized by alkylating 5,5-bis(thiomethyl)-2,4-imidazolidinedione with halomethyl arom. or halomethyl heteroarom. precursors or by using the Buchener-Berg procedure on the required ketone. This series of 5,5-disubstituted Hydantoin derivs. are biol. active in their ability to inhibit HIV-induced death and virus prodn. in mammalian (human) cells. Thus, 5,5-bis(thiomethyl)-2,4-imidazolidinedione was treated with (bromomethyl)cyclohexane to give 5,5-bis[[(cyclohexylmethyl)methyl]thio]methyl]-2,4-imidazolidinedione (II). The antiviral TC25 of II against CEM cell lines was 8 .mu.M.

IT 208828-00-6P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(prepn. of antiviral 5,5-disubstituted hydantoins)

RN 208828-00-6 HCAPLUS

CN Cysteine, S-phenyl-2-[(phenylthio)methyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 4 OF 9 HCAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1998:208523 HCAPLUS

DOCUMENT NUMBER: 128:270437

TITLE: Preparation of .beta.-sulfonyl hydroxamic acids as matrix metalloproteinases inhibitors

INVENTOR(S): Warpehoski, Martha A.; Harper, Donald E.

PATENT ASSIGNEE(S): Pharmacia & Upjohn Co., USA; Warpehoski, Martha A.; Harper, Donald E.

SOURCE: PCT Int. Appl., 57 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9813340	A1	19980402	WO 1997-US16348	19970919
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9746459	A1	19980417	AU 1997-46459	19970919
AU 726799	B2	20001123		
EP 929519	A1	19990721	EP 1997-945207	19970919
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, NL, SE, PT, IE, FI				
BR 9712134	A	19990831	BR 1997-12134	19970919
CN 1230177	A	19990929	CN 1997-197922	19970919
JP 2001516338	T2	20010925	JP 1998-515702	19970919
NO 9901494	A	19990526	NO 1999-1494	19990326
KR 2000048639	A	20000725	KR 1999-702581	19990326
US 6235928	B1	20010522	US 1999-269185	19990726
PRIORITY APPLN. INFO.:			US 1996-26848P	P 19960927
			WO 1997-US16348	W 19970919

OTHER SOURCE(S): MARPAT 128:270437


AB HONHCOCHR2CH2SO2R1 [R1 = C4-12 alk(en)yl, C4-12 alkynyl, (CH2)hC3-8 cycloalkyl, (un)substituted (CH2)haryl, cyano, etc.; R2 = (un)substituted C1-12 alkyl, (un)substituted C2-12 alkenyl or alkynyl, (un)substituted (CH2)hC3-8cycloalk(en)yl, (un)substituted (CH2)haryl, etc.; h = 0-6] or their pharmaceutical acceptable salts were prep'd. as inhibitors of matrix metalloproteinases involved in tissue degradn. For example, refluxing 12 mmol 2-(bromomethyl)acrylic acid overnight with 27 mmol p-MeC6H4SO2Na.cntdot.H2O in 50 mL PhMe in the presence of 12 mmol NaHCO3 gave 2-[(4-methylbenzenesulfonyl)methyl]-3-(4-methylbenzenesulfonyl)propionic acid which (11 mmol) was stirred overnight with 22 mmol 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide-HCl and 22 mmol HONH2.cntdot.HCl in 20 mL N-methylpyrrolidone to give a title compd. p-MeC6H4SO2CH2CH(CONHOH)CH2SO2C6H4Me-p. The latter in vitro inhibited stromelysin and gelatinase with Ki 0.13 .mu.M and 0.0038 .mu.M, resp.

IT 205504-40-1P 205504-41-2P 205504-42-3P
 205504-45-6P 205504-46-7P 205504-49-0P
 205504-50-3P 205504-51-4P 205504-52-5P
 205504-55-8P 205504-56-9P 205504-57-0P
 205504-58-1P 205504-59-2P 205504-60-5P
 205504-61-6P 205504-62-7P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of .beta.-sulfonyl hydroxamic acids as matrix metalloproteinases inhibitors)

RN 205504-40-1 HCAPLUS


CN Propanamide, N-hydroxy-3-[(4-methoxyphenyl)sulfonyl]-2-[[4-methoxyphenyl)sulfonyl)methyl]- (9CI) (CA INDEX NAME)




RN 205504-41-2 HCAPLUS
 CN Propanamide, 3-[[4-chlorophenyl]sulfonyl]-2-[[4-chlorophenyl]sulfonyl]methyl]-N-hydroxy- (9CI) (CA INDEX NAME)




RN 205504-42-3 HCAPLUS
 CN Propanamide, 3-[[4-bromophenyl]sulfonyl]-2-[[4-bromophenyl]sulfonyl]methyl]-N-hydroxy- (9CI) (CA INDEX NAME)




RN 205504-45-6 HCAPLUS
 CN Propanamide, N-hydroxy-3-[[4-methylphenyl]sulfonyl]-2-[[4-methylphenyl]sulfonyl]methyl]- (9CI) (CA INDEX NAME)




RN 205504-46-7 HCAPLUS
 CN Propanamide, N-hydroxy-3-(phenylsulfonyl)-2-[(phenylsulfonyl)methyl]- (9CI) (CA INDEX NAME)




RN 205504-49-0 HCAPLUS
 CN 1-Imidazolidinepropanamide, N-hydroxy-.alpha.-[[[4-methoxyphenyl)sulfonyl]methyl]-3-methyl-2,5-dioxo- (9CI) (CA INDEX NAME)




RN 205504-50-3 HCAPLUS
 CN 1-Imidazolidinepropanamide, .alpha.-[[[4-butoxyphenyl)sulfonyl]methyl]-3-butyl-N-hydroxy-2,5-dioxo- (9CI) (CA INDEX NAME)



RN 205504-51-4 HCAPLUS
 CN 1-Imidazolidinepropanamide, 3-butyl-N-hydroxy-.alpha.-[[[4-methoxyphenyl)sulfonyl]methyl]-2,5-dioxo- (9CI) (CA INDEX NAME)




RN 205504-52-5 HCAPLUS
 CN 1-Imidazolidinepropanamide, N-hydroxy-.alpha.-[[[4-methoxyphenyl)sulfonyl]methyl]-4,4-dimethyl-2,5-dioxo- (9CI) (CA INDEX NAME)




RN 205504-55-8 HCAPLUS
 CN 1-Imidazolidinepropanamide, N-hydroxy-.alpha.-[[[4-methoxyphenyl)sulfonyl]methyl]-3-methyl-2,5-dioxo-, (+)-(9CI) (CA INDEX NAME)

Rotation (+).




RN 205504-56-9 HCAPLUS
 CN 1-Imidazolidinepropanamide, N-hydroxy-.alpha.-[[[4-methoxyphenyl)sulfonyl]methyl]-3-methyl-2,5-dioxo-, (-)-(9CI) (CA INDEX NAME)

Rotation (-).



RN 205504-57-0 HCAPLUS
 CN 1-Imidazolidinepropanamide, .alpha.-[[[4-butoxyphenyl)sulfonyl]methyl]-3-butyl-N-hydroxy-2,5-dioxo-, (+)-(9CI) (CA INDEX NAME)


Rotation (+).



RN 205504-58-1 HCAPLUS

CN 1-Imidazolidinepropanamide, .alpha.-[[[(4-butoxyphenyl)sulfonyl]methyl]-3-butyl-N-hydroxy-2,5-dioxo-, (-)- (9CI) (CA INDEX NAME)


Rotation (-).



RN 205504-59-2 HCAPLUS

CN 1-Imidazolidinepropanamide, 3-butyl-N-hydroxy-.alpha.-[[[(4-methoxyphenyl)sulfonyl]methyl]-2,5-dioxo-, (+)- (9CI) (CA INDEX NAME)


Rotation (+).



RN 205504-60-5 HCAPLUS


CN 1-Imidazolidinepropanamide, 3-butyl-N-hydroxy-.alpha.-[[[(4-methoxyphenyl)sulfonyl]methyl]-2,5-dioxo-, (-)- (9CI) (CA INDEX NAME)

Rotation (-).




RN 205504-61-6 HCAPLUS
 CN 1-Imidazolidinepropanamide, N-hydroxy-.alpha.-[[[4-methoxyphenyl)sulfonyl]methyl]-4,4-dimethyl-2,5-dioxo-, (+)- (9CI) (CA INDEX NAME)

Rotation (+).



RN 205504-62-7 HCAPLUS
 CN 1-Imidazolidinepropanamide, N-hydroxy-.alpha.-[[[4-methoxyphenyl)sulfonyl]methyl]-4,4-dimethyl-2,5-dioxo-, (-)- (9CI) (CA INDEX NAME)

Rotation (-).




IT 205504-67-2P 205504-68-3P 205504-70-7P
 205504-74-1P 205504-87-6P 205504-88-7P
 205504-90-1P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (prepn. of .beta.-sulfonyl hydroxamic acids as matrix metalloproteinases inhibitors)

RN 205504-67-2 HCAPLUS


CN Propanoic acid, 3-[[[4-methoxyphenyl)thio]-2-[[[4-methoxyphenyl)thio]methyl]- (9CI) (CA INDEX NAME)




RN 205504-68-3 HCAPLUS
 CN Propanoic acid, 3-[(4-methoxyphenyl)sulfonyl]-2-[[4-methoxyphenyl)sulfonyl]methyl]- (9CI) (CA INDEX NAME)




RN 205504-70-7 HCAPLUS
 CN Propanoic acid, 3-[(4-chlorophenyl)sulfonyl]-2-[[4-chlorophenyl)sulfonyl]methyl]- (9CI) (CA INDEX NAME)




RN 205504-74-1 HCAPLUS
 CN Propanoic acid, 3-[(4-methylphenyl)sulfonyl]-2-[[4-methylphenyl)sulfonyl]methyl]- (9CI) (CA INDEX NAME)




RN 205504-87-6 HCAPLUS
 CN 1-Imidazolidinepropanoic acid, .alpha.-[[4-methoxyphenyl)thio]methyl]-3-methyl-2,5-dioxo- (9CI) (CA INDEX NAME)



RN 205504-88-7 HCAPLUS
 CN 1-Imidazolidinepropanoic acid, .alpha.-[[[(4-methoxyphenyl)sulfonyl]methyl]-3-methyl-2,5-dioxo- (9CI) (CA INDEX NAME)



RN 205504-90-1 HCAPLUS
 CN 1-Imidazolidinepropanoic acid, .alpha.-[[[(4-butoxyphenyl)sulfonyl]methyl]-3-butyl-2,5-dioxo- (9CI) (CA INDEX NAME)



L12 ANSWER 5 OF 9 HCAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER:

1997:549278 HCAPLUS

DOCUMENT NUMBER:

127:161589

TITLE:

Preparation of substituted (aryl, heteroaryl, arylmethyl or heteroarylmethyl) hydroxamic acid compounds for inhibiting the prodn. or physiol. effects of TNF and cAMP phosphodiesterase.

INVENTOR(S):

Groneberg, Robert D.; Neuenschwander, Kent W.; Djuric, Stevan W.; Mcgeehan, Gerard M.; Burns, Christopher J.; Condon, Steven M.; Morrisette, Matthew M.; Salvino, Joseph M.; Scotese, Anthony C.; Ullrich, John W.; et al.

PATENT ASSIGNEE(S):

Rhone-Poulenc Rorer Pharmaceuticals Inc., USA; Groneberg, Robert D.; Neuenschwander, Kent W.; Djuric, Stevan W.; Mcgeehan, Gerard M.; Burns, Christopher J.; Condon, Steven M.; Morrisette, Matthew M.

SOURCE:

PCT Int. Appl., 251 pp.

CODEN: PIXXD2

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT:

8

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9724117	A1	19970710	WO 1997-US264	19970102
W:	AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
AU 9715298	A1	19970728	AU 1997-15298	19970102
EP 871439	A1	19981021	EP 1997-901388	19970102
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI			

JP 2000503012	T2	20000314	JP 1997-524642	19970102
US 6057369	A	20000502	US 1997-928943	19970912
US 6133409	A	20001017	US 1998-103872	19980624
US 6392010	B1	20020521	US 1999-469829	19991222

PRIORITY APPLN. INFO.:

US 1996-9484P	P	19960102
US 1996-32453P	P	19961219
US 1996-33881P	P	19961224
WO 1997-US264	W	19970102
US 1997-928943	A2	19970912
WO 1997-US23920	A2	19971217
US 1998-103872	A2	19980624
WO 1999-US14251	A2	19990623

OTHER SOURCE(S): MARPAT 127:161589

AB The title compds. HONHCOCpR1R2CR3R4[S(O)n]qCmR5R6Ar [I; R1 = H, optionally substituted alkyl, alkenyl, or cycloalkyl, etc.; R2, R4-R6 = H, optionally substituted alkyl, etc.; R3 = optionally substituted alkyl, alkenyl, cycloalkenyl, or cycloalkyl, etc.; Ar = (un)substituted aryl or heteriaryl; n = 0-2; m = 0-1; p = 0-1; q = 0-1] are prepd. I, possessing tumor necrosis factor (TNF), matrix metalloproteinase (MMP), and cAMP phosphodiesterase inhibitory activity, are useful for prevention and treatment of a patient suffering from a disease state assocd. with a physiol. detrimental excess of tumor necrosis factor (TNF) and disease states including inflammatory and autoimmune diseases, etc. Thus, C6H5(CH2)4CH(SO2C6H5)CH2CO2H (prepn. given) was treated with (COCl)2 and then reacted with TMSONH2 to give the title compd. C6H5(CH2)4CH(SO2C6H5)CH2CONHOH.

IT 193550-69-5P 193550-70-8P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. of substituted (aryl, heteroaryl, arylmethyl or heteroarylmethyl) hydroxamic acid compds. for inhibiting the prodn. or physiol. effects of TNF and cAMP phosphodiesterase.)

RN 193550-69-5 HCAPLUS

CN Benzeneheptanoic acid, .beta.-[(4-methoxyphenyl)sulfonyl]-.alpha.-[(phenylthio)methyl]-, (R*,R*)- (9CI) (CA INDEX NAME)


Relative stereochemistry.




RN 193550-70-8 HCAPLUS

CN Benzeneheptanamide, N-hydroxy-.beta.-[(4-methoxyphenyl)sulfonyl]-.alpha.-[(phenylthio)methyl]-, (R*,S*)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



L12 ANSWER 6 OF 9 HCAPLUS COPYRIGHT 2002 ACS
 ACCESSION NUMBER: 1990:531906 HCAPLUS
 DOCUMENT NUMBER: 113:131906
 TITLE: The synthesis of butenolide .alpha.-formyl acetals
 AUTHOR(S): Kejian, Chen; Sanner, Mark A.; Carlson, Robert M.
 CORPORATE SOURCE: Dep. Chem., Univ. Minnesota, Duluth, MN, 55812, USA
 SOURCE: Synthetic Communications (1990), 20(6), 901-6
 CODEN: SYNCAV; ISSN: 0039-7911
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 113:131906
 AB The dianion generated from 3-phenylthio-2-(phenylthiomethyl)propenoic acid adds to a series of carbonyl compds. to give, after methanolysis, .alpha.-dimethoxymethyl-.alpha.-butenolides.
 IT **92806-66-1**
 RL: PROC (Process)
 (conversion of, to butenolide formyl acetals)
 RN 92806-66-1 HCAPLUS
 CN Propanoic acid, 3-(phenylthio)-2-[(phenylthio)methyl]- (9CI) (CA INDEX NAME)



L12 ANSWER 7 OF 9 HCAPLUS COPYRIGHT 2002 ACS
 ACCESSION NUMBER: 1984:591266 HCAPLUS
 DOCUMENT NUMBER: 101:191266
 TITLE: Preparation of tert-butyl 2-(phenylthiomethyl)propenoate, tert-butyl 3-(phenylthio)-2-(phenylthiomethyl)propenoate and related compounds
 AUTHOR(S): Haynes, Richard K.; Katsifis, Andrew; Vonwiller, Simone C.
 CORPORATE SOURCE: Dep. Org. Chem., Univ. Sydney, 2006, Australia
 SOURCE: Aust. J. Chem. (1984), 37(7), 1571-8
 CODEN: AJCHAS; ISSN: 0004-9425
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 101:191266
 AB The prepn. of tert-Bu 2-(phenylthiomethyl)propenoate, tert-Bu and Me 3-(phenylthio)-2-(phenylthiomethyl)propenoate, the corresponding carboxylic acids, and 3-(phenylthio)-2-(phenylsulfinylmethyl)propenoate from 3-bromo-2-(bromomethyl)propionic acid is described.
 IT **92806-66-1P**
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
 (prepn. and attempted chlorination of)
 RN 92806-66-1 HCAPLUS
 CN Propanoic acid, 3-(phenylthio)-2-[(phenylthio)methyl]- (9CI) (CA INDEX NAME)




IT **92806-59-2P 92806-72-9P**

RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

RN 92806-59-2 HCAPLUS

CN 2-Propenoic acid, 3-(phenylthio)-2-[(phenylthio)methyl]-, (E)- (9CI) (CA
INDEX NAME)


Double bond geometry as shown.



RN 92806-72-9 HCAPLUS

CN 2-Propenoic acid, 3-(phenylthio)-2-[(phenylthio)methyl]-, (Z)- (9CI) (CA
INDEX NAME)

Double bond geometry as shown.



L12 ANSWER 8 OF 9 HCAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1972:528090 HCAPLUS

DOCUMENT NUMBER: 77:128090

TITLE: Intermediates for fiber reactive azo dyes

INVENTOR(S): Schuendehuetten, Karl Heinz; Grassmann, Dietrich

PATENT ASSIGNEE(S): Farbenfabriken Bayer A.-G.

SOURCE: Ger. Offen., 20 pp. Division of Ger. offen. 2,057,867.

CODEN: GWXXBX

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2064883	A	19720622	DE 1970-2064883	19701125


AB .alpha.-[(Phenylsulfonyl)methyl]acrylic acid (I) [36526-15-5],
.beta.,.beta.'-bis(phenylsulfonyl)isobutyric acid (II) [36525-59-4]
, .alpha.-[(methylsulfonyl)methyl]acrylic acid (III) [36525-60-7], and
.beta.,.beta.'-bis(methylsulfonyl)isobutyric acid (IV) [36525-61-8] were
prepd. and used in the prepn. of fiber-reactive azo dyes, e.g. azo dye (V)
[36525-69-6]. Thus, refluxing (BrCH₂)₂CHCO₂H and PhSO₂Na in EtOH gave II.
I was similarly prepd. Heating (MeSCH₂)₂CHCO₂H in aq. HOAc contg. H₂O₂ at
80-90.deg. gave III. Reaction of (BrCH₂)₂CHCO₂Et with MeSH, oxidn. with
H₂O₂ in aq. HOAc, and sapon. with aq. HCl gave IV. Reaction of VI with
(PhSO₂CH₂)₂CHCOCl gave V, bluish red on wool.

IT 36525-59-4P

RL: IMF (Industrial manufacture); PREP (Preparation)
(prepn. of)

RN 36525-59-4 HCAPLUS

CN Propanoic acid, 3-(phenylsulfonyl)-2-[(phenylsulfonyl)methyl]- (9CI) (CA
INDEX NAME)



L12 ANSWER 9 OF 9 HCAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1972:516021 HCAPLUS

DOCUMENT NUMBER: 77:116021

TITLE: Fiber-reactive dyes

INVENTOR(S): Suendehuette, Karl Heinz; Grassmann, Dietrich

PATENT ASSIGNEE(S): Farbenfabriken Bayer A.-G.

SOURCE: Ger. Offen., 160 pp.

CODEN: GWXXBX

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2057867	A	19720615	DE 1970-2057867	19701125
NL 7116048	A	19720529	NL 1971-16048	19711122
IT 946087	A	19730521	IT 1971-31510	19711123
BE 775772	A1	19720524	BE 1971-110871	19711124
GB 1366514	A	19740911	GB 1971-54612	19711124
FR 2144185	A5	19730209	FR 1971-42233	19711125

PRIORITY APPLN. INFO.: DE 1970-2057867 19701125


AB Sixty-eight azo, disazo, metallized azo, anthraquinone, Cu phthalocyanine, and nitro dyes contg. $\text{NHCOCH}(\text{CH}_2\text{X})_2$ (X = Br, NMe₂, SO₂Ph) or $\text{NHCOC}(:\text{CH}_2)\text{CH}_2\text{Y}$ groups (Y = pyridinium, carboxypyridinium, triethylenediammonium, N+Et₃, SO₂Ph) were prepd. and used to dye cellulose, nylon, and wool. Prepn. of starting materials contg. the fiber-reactive groups is also described. For example, p-H₂NC₆H₄SO₃Na was diazotized and coupled with 1,8-H₂NC₁₀H₅SO₃H and the intermediate azo compd. was condensed with (BrCH₂)₂CHCOCl to give a reactive azo dye (I) [36339-55-6].

IT 36525-59-4P

RL: IMF (Industrial manufacture); PREP (Preparation)
(prepn. of)

RN 36525-59-4 HCAPLUS

CN Propanoic acid, 3-(phenylsulfonyl)-2-[(phenylsulfonyl)methyl]- (9CI) (CA INDEX NAME)



=> fil caold

FILE 'CAOLD' ENTERED AT 08:18:32 ON 22 OCT 2002

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1907-1966

FILE LAST UPDATED: 01 May 1997 (19970501/UP)

This file contains CAS Registry Numbers for easy and accurate substance identification. Title keywords, authors, patent assignees, and patent information, e.g., patent numbers, are now searchable from 1907-1966. TIFF images of CA abstracts printed between 1907-1966 are available in the PAGE display formats.

This file supports REGISTRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

=>

=> s l2

L13 0 L2

=> fil hcaplus
 FILE 'HCAPLUS' ENTERED AT 08:23:00 ON 22 OCT 2002
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.


FILE COVERS 1907 - 22 Oct 2002 VOL 137 ISS 17
 FILE LAST UPDATED: 21 Oct 2002 (20021021/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

CAS roles have been modified effective December 16, 2001. Please check your SDI profiles to see if they need to be revised. For information on CAS roles, enter HELP ROLES at an arrow prompt or use the CAS Roles thesaurus (/RL field) in this file.

=>
 =>



=> d stat que
 L1 STR



REP G1=(0-1) N
 VAR G2=16/18/21/24/25/27/29/31/32
 NODE ATTRIBUTES:
 DEFAULT MLEVEL IS ATOM
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 36


STEREO ATTRIBUTES: NONE
L2 241 SEA FILE=REGISTRY SSS FUL L1
L3 STR



REP G1=(0-1) N
VAR G2=16/18/21/24/25/27/29/31/32
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 36


STEREO ATTRIBUTES: NONE
L4 (241)SEA FILE=REGISTRY SSS FUL L3
L5 STR



REP G1=(0-1) N
 VAR G2=16/18/21/24/25/27/29/31/32
 VAR G3=39/46/47/48
 NODE ATTRIBUTES:
 DEFAULT MLEVEL IS ATOM
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
 RING(S) ARE ISOLATED OR EMBEDDED
 NUMBER OF NODES IS 52

STEREO ATTRIBUTES: NONE
 L6 100 SEA FILE=REGISTRY SUB=L4 SSS FUL L5
 L7 STR



VAR G2=16/18/21/24/25/27/29/31/32

NODE ATTRIBUTES:
 DEFAULT MLEVEL IS ATOM
 DEFAULT ECLEVEL IS LIMITED


GRAPH ATTRIBUTES:
 RING(S) ARE ISOLATED OR EMBEDDED
 NUMBER OF NODES IS 35

STEREO ATTRIBUTES: NONE

L9 184 SEA FILE=REGISTRY SSS FUL L7
 L10 12 SEA FILE=HCAPLUS ABB=ON PLU=ON L2
 L11 3 SEA FILE=HCAPLUS ABB=ON PLU=ON L6
 L12 9 SEA FILE=HCAPLUS ABB=ON PLU=ON L10 NOT L11
 L18 16 SEA FILE=HCAPLUS ABB=ON PLU=ON L9
 L19 4 SEA FILE=HCAPLUS ABB=ON PLU=ON L18 NOT (L11 OR L12)

=> d ibib abs hitstr l19 1-4

L19 ANSWER 1 OF 4 HCAPLUS COPYRIGHT 2002 ACS
 ACCESSION NUMBER: 1997:338556 HCAPLUS
 DOCUMENT NUMBER: 127:50112
 TITLE: Free radical addition reactions of allylic sulfones to alkenes
 AUTHOR(S): Harvey, Iain W.; Phillips, Eifion D.; Whitham, Gordon H.
 CORPORATE SOURCE: Dyson Perrins Laboratory, University of Oxford, OXFORD, OX1 3QY, UK
 SOURCE: Tetrahedron (1997), 53(18), 6493-6508
 CODEN: TETRAB; ISSN: 0040-4020
 PUBLISHER: Elsevier
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 127:50112
 AB Intermol. radical reactions involving formal addn. of the sulfonyl and allyl fragments of an allylic sulfone across the double bond of an alkene are described. Reactions are most successful when the allylic sulfone has an electron withdrawing group at the 2-position. Only monosubstituted alkenes give useful yields of adducts, though both electron withdrawing and electron donating substituents are effective.
 IT **191152-59-7P**
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. and free radical addn. reactions of allylic sulfones to alkenes)
 RN 191152-59-7 HCAPLUS
 CN Pentanedioic acid, 4-methylene-2,2-bis[[(4-methylphenyl)sulfonyl]methyl]-, dimethyl ester (9CI) (CA INDEX NAME)



L19 ANSWER 2 OF 4 HCAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1993:494702 HCAPLUS

DOCUMENT NUMBER: 119:94702

TITLE: Preparation of functionalized Z-olefins using 1,1-dimetalloalkanes

AUTHOR(S): Tucker, Charles E.; Knochel, Paul

CORPORATE SOURCE: Dep. Chem., Univ. Michigan, Ann Arbor, MI, 48109, USA

SOURCE: Synthesis (1993), (5), 530-6

CODEN: SYNTBF; ISSN: 0039-7881

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 119:94702


AB 1,1-Dimetalloalkanes $\text{CH}_2\text{:CRCH}_2\text{CHR}_1\text{CH(MgBr)ZnBr}$ ($\text{R} = \text{H}$, $\text{R}_1 = \text{H}$, $n\text{-C}_6\text{H}_{13}$; $\text{R} = \text{Bu}$, $\text{R}_1 = \text{H}$), obtained by the allylzincation of alkenylmagnesium compds., react smoothly with various functionalized alkylidenemalonates providing functionalized Z-olefins $(\text{Z})\text{-CH}_2\text{:CRCH}_2\text{CHR}_1\text{CH:CHR}_2$ [$\text{R}_2 = (\text{CH}_2)_3\text{CO}_2\text{Et}$, cyclohexyl, PhSiMe_2 , etc.] in good yields. If dimethyl alkylidenemalonates are used, then excellent stereoselectivities are obsd. (92:8 to 100:0). An application to a short stereospecific synthesis of an insect pheromone [(Z)-7-dodecenyl acetate] is described (>99.9% Z, 70% overall yield).

IT 130247-47-1P 149221-99-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and reaction of, with zinc-copper reagent)


RN 130247-47-1 HCAPLUS

CN Propanedioic acid, [(phenylsulfonyl)methylene]-, dicyclohexyl ester (9CI)
(CA INDEX NAME)




RN 149221-99-8 HCAPLUS


CN Propanedioic acid, [(phenylsulfonyl)methylene]-, bis[5-methyl-2-(1-methylethyl)cyclohexyl] ester, [1R-[1.alpha.(1R*,2S*,5R*),2.beta.,5.alpha.]]- (9CI) (CA INDEX NAME)



L19 ANSWER 3 OF 4 HCAPLUS COPYRIGHT 2002 ACS
 ACCESSION NUMBER: 1991:655652 HCAPLUS
 DOCUMENT NUMBER: 115:255652
 TITLE: Stereo- and regioselective synthesis of
 polyfunctionalized cyclopropanes
 AUTHOR(S): Tanaka, Kazuhiko; Matsuura, Hideki; Funaki, Ikuo;
 Suzuki, Hitomi
 CORPORATE SOURCE: Fac. Sci., Kyoto Univ., Kyoto, 606, Japan
 SOURCE: Journal of the Chemical Society, Chemical
 Communications (1991), (17), 1145-6
 CODEN: JCCCAT; ISSN: 0022-4936
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 115:255652
 GI



AB The reaction of 3-phenylthio-2-(phenylthiomethyl)propanal (I) with
 organolithium reagents provides a stereo- and regioselective one-pot route
 to polyfunctionalized cyclopropane derivs. E.g., reaction of I with MeLi,
 followed by BuLi and quenching with H₂O, gave cyclopropylethanol deriv. I
 stereoselectively.
 IT **92806-63-8**
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (redn. of)
 RN 92806-63-8 HCAPLUS
 CN Propanoic acid, 3-(phenylthio)-2-[(phenylthio)methyl]-, methyl ester (9CI)
 (CA INDEX NAME)



L19 ANSWER 4 OF 4 HCAPLUS COPYRIGHT 2002 ACS
 ACCESSION NUMBER: 1990:610954 HCAPLUS
 DOCUMENT NUMBER: 113:210954
 TITLE: The olefination of functionalized alkylidenemalonates
 by 1,1-dimetalloalkanes: a new chemo- and
 stereoselective preparation of functionalized olefins
 AUTHOR(S): Tucker, Charles E.; Rao, S. Achyutha; Knochel, Paul
 CORPORATE SOURCE: Dep. Chem., Univ. Michigan, Ann Arbor, MI, 48109, USA
 SOURCE: Journal of Organic Chemistry (1990), 55(20), 5446-8
 CODEN: JOCEAH; ISSN: 0022-3263
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 113:210954
 AB Polyfunctional alkylidenemalonates were converted under very mild
 conditions (-20.degree., 10 min) and in excellent yields (76-91%) to
 highly functionalized olefins by reaction with 1-magnesia-1-zincaalkenes.
 The newly formed double bond has mainly the Z configuration (typically,

Z:E ratios of 80:20). The nature of the alkylidenemalonate and 1,1-dimetallalkane substituents influence the Z/E ratio, and a ratio up to 100:0 could be reached. The polyfunctional alkylidenemalonates were prepd. by a new efficient method using the addn. of highly functionalized copper-zinc reagents to [(phenylsulfonyl)methylidene]malonates 9-30.degree., 1h, 40-90% yield). An application of this methodol. to the prepn. of the insect pheromone (Z)-1-acetoxy-7-dodecene is reported (2 steps, 70% overall yield, >99.9% Z isomer).

IT **130247-47-1P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and reaction with copper-zinc reagents)

RN 130247-47-1 HCAPLUS

CN Propanedioic acid, [(phenylsulfonyl)methylene]-, dicyclohexyl ester (9CI)
(CA INDEX NAME)

